The hepatitis B diagnostic tests market size was projected to be worth USD 872.5 million in 2022. By the end of 2023, the market is likely to reach a valuation of USD 872.5 million. The global market for hepatitis B diagnostic tests is likely to garner a 6.5% CAGR and reach a market worth USD 1744.26 million by 2033.
Key Market Trends and Highlights
| Attributes | Key insights |
|---|---|
| Estimated Market Value in 2022 | USD 872.5 million |
| Expected Market Value in 2023 | USD 872.5 million |
| Expected Market Value in 2033 | USD 1744.26 million |
| Value-based CAGR from 2023 to 2033 | 6.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
During the historical period, 2018 to 2022, the hepatitis B diagnostic tests market grew at CAGR of 4.5%.
| Report Attributes | Details |
|---|---|
| Market value in 2018 | USD 678.21 million |
| Market value in 2022 | USD 872.5 million |
| CAGR from 2018 to 2022 | 4.5% |
The need for hepatitis B diagnostic tests is significantly increased by public health efforts and screening programs. To inform people about the dangers of hepatitis B and the value of testing, healthcare organizations, governments, and non-governmental organizations frequently conduct awareness campaigns as well as screening programs.
The general public and healthcare professionals become more informed as a result of these initiatives, which raise the rates of screening and diagnosis. The market for hepatitis B diagnostic tests is driven by rising testing rates and better access to testing facilities.
Principal Consultant
Below mentioned is the table of top five countries that are anticipated to gain a significant growth rate during the forecast period. Among these countries, the maximum growth is expected from two specific countries, namely the United States and China.
Forecast CAGRs from 2023 to 2033
| Country | Expected market share in 2023 |
|---|---|
| The United States | 34.7% |
| China | 23.2% |
| Japan | 7.1% |
| France | 8.0% |
| The United Kingdom | 7.8% |
In 2023, the United States market for Hepatitis B Diagnostic Tests is anticipated to take over 34.7% market share. In the United States, there is a higher demand for diagnostic tests as people become more aware of the necessity of hepatitis B testing along with the accompanying health hazards.
More people are being screened for hepatitis B through various educational activities, public health campaigns, and healthcare practitioner recommendations. This increased awareness has resulted in higher test rates and increased demand for diagnostic tests.
Hepatitis B is the most common cause of liver illness and malignancy. Individuals, particularly those with associated risks like a family history of hepatitis B or particular habits, are increasingly seeking preventative healthcare due to the significance of liver health.
Hepatitis B testing on a regular basis allows for early identification and treatment, which can help avoid liver damage and problems. The focus on preventative medicine and to live a better way is bolstering the regional demand all across the United States.
In 2023, China is anticipated to acquire 23.2% of the global market shares for hepatitis B diagnostic tests. As per WHO, China has the world's highest prevalence of hepatitis B cases. Currently, there are approximately 70 million HBV-infected persons in China. To alleviate this burden, immunization, counseling, and early detection will be critical. The Chinese government has also initiated a number of programs aimed at eradicating this deadly disease by 2030. To achieve this purpose, it collaborates closely with international bodies such as WHO.
A sizable portion of the population in China is at an increased risk for hepatitis B owing to the virus's high prevalence in some areas and its numerous transmission routes. Children born to hepatitis B-positive mothers are among those at risk, resulting in increasing need for child and maternal health screening along with general hepatitis B screening.
In recent years, China has undergone considerable healthcare reforms, with an emphasis on increasing healthcare availability and quality. The government's effort to promote public health includes programs to improve hepatitis B awareness and extend access to diagnostic services. These initiatives have contributed to increasing demand for hepatitis B testing as greater numbers of individuals seek screening as well as prompt detection.
The hepatitis B diagnostic tests market in Japan will gain 7.1% of the global market share by the end of 2023. Japan is drawing an increasing number of medical tourists looking for superior healthcare treatments. Hepatitis B testing may be required for some of these medical tourists as part of the pre-surgical or pre-treatment evaluations. This surge of overseas patients increases need for diagnostic testing.
Japan's population is aging, and elderly people are more likely to develop problems from an ongoing infection with hepatitis B. The healthcare system in the nation places a heavy focus on regular medical examinations and preventative treatment for elders. There is an increasing demand for hepatitis B diagnostic tests for tracking and managing the senior population's health.
The hepatitis B diagnostic tests market in France is anticipated to gain 8% market share by 2023. France is well-known for its outstanding healthcare system along with universal coverage. Preventive treatments and frequent screenings are stressed as part of comprehensive healthcare. Screening for Hepatitis B is frequently advised and given to a wide spectrum of patients, leading to the continued need for diagnostic testing.
France's population is varied, including immigrants from locations with differing hepatitis B incidence rates. Individuals from these areas are frequently advised by healthcare experts to be tested for hepatitis B. The need for diagnostic testing is driven by cultural diversity along with healthcare access legislation.
The United Kingdom Hepatitis B Diagnostic Tests market is expected to acquire a 7.8% market share by 2023. The United Kingdom has various launched immunization efforts to prevent both acute and demand for Chronic Hepatitis B Virus Testing. As part of these initiatives, healthcare clinicians may suggest hepatitis B testing to those who are at high risk owing to their travel history, work, or other reasons. This emphasis on immunization and focused testing leads to the increased demand for hepatitis B diagnostic tests in the United Kingdom.
The country also places a major emphasis on liver disorder awareness and research. Many organizations and universities perform considerable research on liver illnesses such as hepatitis B. Increased screening as well as diagnostic testing is frequently the result of this investigation, particularly in high-risk groups.
The National Health Service (NHS) in the United Kingdom provides comprehensive medical services to inhabitants. Frequent health check-ups as well as screening programs are essential components of the NHS's preventative care strategy. Hepatitis B testing is offered in some screening programs and thus advised for at-risk persons, which adds to the need for diagnostic tests.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below table highlights how the enzyme immunoassay kits are projected to lead the global market in terms of product type. These products are expected to acquire 71.90% market share in 2023.
The hepatitis B diagnostic tests being used up in hospitals sector have gained immense traction in the last few years. During the forecast period, the hospitals segment will grow with a fast 6.2% CAGR.
| Category | Market share in 2023/ CAGR(2023 to 2033) |
|---|---|
| Enzyme immunoassay kits | 71.9% |
| Hospitals | 6.2% |
Enzyme immunoassay kits account for over 70% of the global hepatitis B diagnostic tests market. It is anticipated to expand profitably at a CAGR of 6.2% in the next ten years.
The enzyme immunoassay kits are commonly employed in the detection of hepatitis B infection due to their dependability and ease of use. Since enzyme immunoassay kits are made to be extremely specific and highly sensitive, they can accurately detect even minute levels of hepatitis B surface antigen (HBsAg) or antibodies. They can therefore distinguish between instances that are acute and those that are chronic and are useful for early infection diagnosis.
Results from enzyme immunoassay kits are normally available in a matter of hours. This short turnaround time is beneficial for patients as well as healthcare providers since it enables prompt hepatitis B diagnosis and treatment, which can lower the risk of complications and transmission.
Based on end-use, the hospitals segment is expected to continue gaining traction in the global hepatitis B diagnostic tests industry. The segment is anticipated to gain a CAGR of 6.2% throughout the forecast period.
The population of prospective patients who might use medical services is expanding along with the number of hospitals. Hospitals are important healthcare centers where people frequently undergo testing for various kind of diseases including hepatitis B diagnosis. This bigger patient pool raises the need for hepatitis B diagnostic tests, which expands the market.
The geographic reach of healthcare services can be increased via the construction of new hospitals, especially in underserved or distant locations. Groups that may have previously had limited access to hepatitis B diagnostic tests may now have greater access to them. As more individuals are tested for hepatitis B, the wider scope of diagnostic testing may aid in the growth of global Hepatitis - B Therapeutics.
Manufacturers of HBV diagnostics tests make investments in research and development to provide cutting-edge, novel testing products. Enhanced test sensitivity and specificity, shorter turnaround times, intuitive user interfaces, and interoperability with automated laboratory equipment are a few examples of these improvements.
Manufacturers want to gain market share and satisfy the rising need for precise and effective testing procedures by releasing new and enhanced diagnostic assays and instruments.
Some of the prominent developments by key companies in this domain are:
| Company | Key Developments |
|---|---|
| Gilead Sciences, Inc. |
|
| Abbott |
|
| GSK |
|
| Attribute | Details |
|---|---|
| Projected market value in 2023 | USD 872.5 million |
| Projected market value in 2033 | USD 1744.26 million |
| Forecast CAGR from 2023 to 2033 | 6.5% |
| Forecast period | 2023 to 2033 |
| Historical period | 2018 to 2022 |
| Market analysis | Value in USD million |
| Key regions covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East & Africa |
| Key countries profiled | The United States, Canada, Brazil, Mexico, Germany, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC countries, South Africa, Israel |
| Key market segments | Product Type, End-user, Region |
| Key companies profiled | Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; Abbott Laboratories; Meridian Bioscience; bioMérieux SA Inc.; Vista Diagnostics International; Biogate Laboratories Ltd.; J.Mitra & Co. Ltd.; Siemens Medical Solutions USA, Inc.; General Biologicals Corporation |
The hepatitis B diagnostic tests market is expected to reach USD 872.5 million by 2023.
The global Hepatitis B Diagnostic Tests market is set to expand by a CAGR of 6.5% by 2033.
The hepatitis B diagnostic tests industry is forecast to reach USD 1744.26 million by 2033.
The enzyme immunoassay test kits are expected to acquire over 70% in 2023 and same trend will continue.
Through 2033, the hospitals segment will garner over 6% CAGR.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Enzyme Immunoassay Kits 5.1.1. Hepatitis B Surface Antigen Test 5.1.2. Anti-Hepatitis B Surface Antibody Test 5.1.3. Anti-Hepatitis B Core Antibody Test 5.2. Point-of-Care Testing Kits 5.2.1. Strips 5.2.2. Cassettes/Cards 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Clinics 6.3. Diagnostic Centres 6.4. Home Care 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Bio-Rad Laboratories, Inc. 17.2. DiaSorin S.p.A. 17.3. Abbott Laboratories 17.4. Meridian Bioscience 17.5. bioMérieux SA Inc. 17.6. Vista Diagnostics International 17.7. Overview 17.8. J.Mitra & Co. Ltd. 17.9. Siemens Medical Solutions USA, Inc. 17.10. General Biologicals Corporation 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Hepatitis B Diagnostic Tests Market
